

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Physician
Dr. Jamshid Shirani
Close
Synopsis: The purpose of this study is to compare the effect of the investigational drug, mavacamten, to a placebo (an inactive drug). This is being done to confirm that in obstructive Hypertrophic Cardiomyopathy (HCM) patients mavacamten is safe, and helps to improve symptoms or ability to exercise.
Mavacamten is an investigational drug, referred to as “study drug” in this consent form. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of HCM.
MyoKardia Inc. is the sponsor of this study, also referred to as “MyoKardia.” MyoKardia is providing the study drug and is compensating the study doctor and site staff to conduct the study.
Close
Close
Close
Interested in a
Clinical Trial?